Phase 3 ePHex Study: OxThera Reports Results
OxThera AB, a UF Innovate | Sid Martin Biotech alum and privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces completion of its pivotal Phase 3 study and reports top line results.
OxThera’s 52-week OC5-DB-02 study “A Phase III Double-Blind, Randomised Study to Evaluate the Long-Term Efficacy and Safety of Oxabact® in Patients with Primary Hyperoxaluria” (ePHex) enrolled patients with all types of PH, who had to have a plasma oxalate (Pox) concentration ≥ 10 μmol/L and an eGFR < 90 ml/min/1.73 m2 during screening to be eligible for inclusion into the study.
Read more about OxThera Reports Results From Phase 3 ePHex Study With Oxabact in Primary Hyperoxaluria Patients With Maintained Kidney Function.